Cases & Deals

  • Home
  • Practices
  • Sanofi and Janssen collaborate to develop vaccines for extra-intestinal pathogenic E. coli

Share

Sanofi and Janssen collaborate to develop vaccines for extra-intestinal pathogenic E. coli

November 2023

Client(s) Sanofi

Jones Day represented and supported Sanofi's in-house team in its strategic collaboration with Janssen Pharmaceuticals, now “Johnson & Johnson Innovative Medicine," in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to the development and commercialization of vaccines for extra-intestinal pathogenic E. coli. Both parties will co-fund current and future research and development costs, followed by development and commercial milestones. Sanofi will share profits in the U.S., France, Germany, Italy, Spain, and the UK; and Janssen will receive tiered royalties and sales milestones in the rest of world.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.